Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


GSK’s New Year’s resolution

This article was originally published in The Tan Sheet

Executive Summary

GlaxoSmithKline Consumer Healthcare will make its Committed Quitters online smoking cessation support program available for free to all smokers wishing to quit in the New Year, according to a Dec. 14 announcement by the Nicorette and NicoDerm marketer. Beginning Dec. 12, smokers can access the program's 1website for information and individualized tools and tips to deal with psychological challenges that accompany quitting. Previously, the online program was available only to those who purchased GSK smoking cessation products. A study in the May issue of Addiction finds that smokers who used the Committed Quitters program with the NicoDerm patch increased their chances of successfully quitting by 28% versus smokers who just used the patch, GSK adds. Separately, the firm recently received FDA approval for a supplemental NDA proposing a new Fruit Chill flavor for Nicorette...

You may also be interested in...

Alli Makes Passing Grade On Safety; Advisory Committee Debates Benefit

Orlistat's benefit in an over-the-countersetting is questionable, but the safety of the weight-loss drug creates a risk/benefit ratio in favor of nonprescription use, an FDA advisory panel expressed in an 11-3 vote Jan. 23

QUOTED. 25 February 2021. Adam Saltman.

A recent FDA action plan on artificial intelligence and machine learning (AI/ML) medical software could encourage more to jump in, said Eko Chief Medical Officer Adam Saltman.

Daiichi's Novel EZH Candidate Moves Ahead With New Consortium Trial

Japanese major links with new partners in European consortium to progress first-in-class molecule for multiple hematological malignancies.





Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts